Details of issuance or disposal
Partial amendment to the issuance terms of the 10th Series Stock Acquisition Rights (paid stock options)
319,464,000 shares (459,000 of these Stock Acquisition Rights, 696 shares per right)
The lower thin line represents the existing number of shares to which these shares will be added.
Total exercise proceeds: approximately ¥3.19 billion; estimated net proceeds: Not disclosed
The number of potential shares after fixation represents approximately 24.9% of the total number of issued shares as of the end of July 2026. The dilution rate against the total number of issued shares after full exercise is approximately 20%.
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.
| Item | Details |
|---|---|
| Type of issuance or disposal | Partial amendment to the issuance terms of the 10th Series Stock Acquisition Rights (paid stock options) |
| Number of shares to be issued or disposed of | 319,464,000 shares (459,000 of these Stock Acquisition Rights, 696 shares per right) |
| Amount of funds to be raised | Total exercise proceeds: approximately ¥3.19 billion; estimated net proceeds: Not disclosed |
| Intended allottee | 5 current holders of these Stock Acquisition Rights (1 director: 276,000 rights; 2 executive officers: 141,000 rights; 2 employees: 42,000 rights) |
| Intended allottee's holding policy | As a general rule, the holders will not sell or transfer the common shares acquired through exercise of the remaining Stock Acquisition Rights from 18 August 2026 through 17 August 2031. Exceptions apply to inheritance upon death and other circumstances, as well as stock lending to parties designated by the Company. |
| Dilution Rate | The number of potential shares after fixation represents approximately 24.9% of the total number of issued shares as of the end of July 2026. The dilution rate against the total number of issued shares after full exercise is approximately 20%. |
| Total number of issued shares | 1,281,283,624 shares (as of 30 June 2026) → Not disclosed |
| Exercise price | ¥10 per share. Adjustment provision: Not disclosed (this disclosure concerns the abolition of the provision for adjusting the number of underlying shares; no description of an adjustment to the exercise price is provided) |
| Exercise period | Rights vest in stages on 8 February 2026, 8 February 2027, and 8 February 2028. Expiration date: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 460,000 rights; exercised: 1,000 rights; remaining unexercised: 459,000 rights |
| Transfer restriction period | 5 years from 18 August 2026 through 17 August 2031 (for shares acquired through exercise) |
| Conditions for lifting transfer restrictions | Inheritance upon death and certain other exceptions. Stock lending to parties designated by the Company is also an exception. |
| Categories and Number of Persons Covered | Current holders: 1 director, 2 executive officers, and 2 employees. Future eligible participants in the incentive vehicle will be current or future officers and employees of the Company or its group companies, among others; number of participants: Not disclosed |
| Procedures under the Corporate Code of Conduct | The Board of Directors approved the matter after excluding the director who holds these Stock Acquisition Rights from deliberation and voting. Consent was obtained from all holders of these Stock Acquisition Rights. |
| Most recent equity financing | February 2023: financing through a third-party allotment of new shares and issuance of the 9th Series Stock Acquisition Rights. Amount: Not disclosed |
| Impact on Business Performance | The impact on consolidated results for the current fiscal year is expected to be immaterial. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To revise the mechanism under which the number of potential shares automatically increases through future equity financings and other events, clarify the upper limit of future dilution for existing shareholders, and clarify the relationship between decisions concerning capital raising and the interests of holders of these Stock Acquisition Rights. In addition, to align the interests of officers and employees with those of shareholders and encourage their commitment to enhancing corporate value over the medium to long term.